S. Andrew Peng

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	EVA-S2PLoR: A Secure Element-wise Multiplication Meets Logistic Regression on Heterogeneous Database	2025	Terence Tao S. Andrew Peng Tianyu Mei S.H. Li Haogang Zhu
+ PDF Chat	EVA-S3PC: Efficient, Verifiable, Accurate Secure Matrix Multiplication Protocol Assembly and Its Application in Regression	2024	S. Andrew Peng Tianrui Liu Terence Tao D.X. Zhao Hao Sheng Haogang Zhu
+	Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update	2019	Rebecca S.S. Tidwell S. Andrew Peng Minxing Chen Diane D. Liu Ying Yuan J. Jack Lee

Common Coauthors

Coauthor	Papers Together
Haogang Zhu	2
Terence Tao	2
Rebecca S.S. Tidwell	1
S.H. Li	1
Diane D. Liu	1
Minxing Chen	1
J. Jack Lee	1
Hao Sheng	1
Tianrui Liu	1
D.X. Zhao	1
Tianyu Mei	1
Ying Yuan	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Clinical Trial Design: Bayesian and Frequentist Adaptive Methods	2011	Guosheng Yin	1
+	Bayes factor and posterior probability: Complementary statistical evidence to p-value	2015	Ruitao Lin Guosheng Yin	1
+	Application of bayesian statistics to decision making during a clinical trial	1992	Laurence S. Freedman David J. Spiegelhalter	1
+	On some applications of bayesian methods in cancer clinical trials	1992	Joel B. Greenhouse	1
+	Description of the statistical aspects of a study for advanced colorectal cancer patients	1992	Samuel Wieand Stephen Cha	1
+ PDF	Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials	2013	Yuan Ji Sue-Jane Wang	1
+ PDF	Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials	2013	Scott Berry Kristine Broglio Susan Groshen Donald A. Berry	1
+ PDF	Adaptive adjustment of the randomization ratio using historical control data	2013	Brian P. Hobbs Bradley P. Carlin Daniel J. Sargent	1
+ PDF	Bayesian optimal interval designs for phase I clinical trials	2014	Suyu Liu Ying Yuan	1
+	The what, why and how of bayesian clinical trials monitoring	1994	Laurence S. Freedman David J. Spiegelhalter Mahesh Parmar	1
+	Designs for group sequential tests	1984	Thomas R. Fleming David P. Harrington Peter C. O’Brien	1
+ PDF	Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center	2009	Swati Biswas Diane D. Liu J. Jack Lee Donald A. Berry	1
+	Stopping a clinical trial early: Frequentist and bayesian approaches applied to a CALGB trial in non‐small‐cell lung cancer	1994	Stephen L. George Chengchang Li Donald A. Berry Mark R. Green	1
+	Cancer phase I clinical trials: efficient dose escalation with overdose control	1998	James S. Babb André Rogatko Shelemyahu Zacks	1
+	Bayesian interim analysis of phase II cancer clinical trials	1997	Daniel F. Heitjan	1
+ PDF	Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes	2014	Ick Hoon Jin Suyu Liu Peter F. Thall Ying Yuan	1
+	Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development	2014	Xuemin Gu Nan Chen Caimiao Wei Suyu Liu Vassiliki A. Papadimitrakopoulou Roy S. Herbst J. Jack Lee	1
+	Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection	2014	Kristine Broglio Jason T. Connor Scott Berry	1
+ PDF	Bayesian clinical trials in action	2012	J. Jack Lee Caleb T. Chu	1
+	Adaptive Clinical Trials	2012	William J. Meurer Roger Lewis Donald A. Berry	1
+	A Bayesian approach to establishang sample size and monitoring criteria for phase II clinical trials	1994	Peter F. Thall Richard Simon	1
+	Some thoughts on sample size: A Bayesian-frequentist hybrid approach	2012	KK Gordan Lan Janet Wittes	1
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	1
+	Comparison of Bayesian with group sequential methods for monitoring clinical trials	1989	Laurence S. Freedman David J. Spiegelhalter	1
+	The Platform Trial	2015	Scott Berry Jason T. Connor Roger Lewis	1
+ PDF	An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project	2012	William J. Meurer Roger J. Lewis Danilo A. Tagle Michael D. Fetters Laurie Legocki Scott Berry Jason Connor Valerie Durkalski Jordan Elm Wenle Zhao	1
+	Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomes	1995	Peter F. Thall Richard Simon Elihu H. Estey	1
+	Monitoring event times in early phase clinical trials: some practical issues	2005	Peter F. Thall Leiko H. Wooten Nizar M. Tannir	1
+	Bayesian clinical trials	2006	Donald A. Berry	1
+ PDF	The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research	2015	Donald A. Berry	1
+	A bayesian strategy for screening cancer treatments prior to phase ii clinical evaluation	1993	Peter F. Thall Elihu H. Estey	1
+	Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods	2012	Maggie H Chen Andrew R. Willan	1
+	TUTORIAL IN BIOSTATISTICS: BAYESIAN DATA MONITORING IN CLINICAL TRIALS	1997	Peter Fayers Deborah Ashby Mahesh Parmar	1
+ PDF	A modified toxicity probability interval method for dose-finding trials	2010	Yuan Ji Ping Liu Yisheng Li B. Nebiyou Bekele	1
+	Bayesian subset analysis in a colorectal cancer clinical trial	1992	Dennis O. Dixon Richard Simon	1
+	Emerging innovations in clinical trial design	2015	DA Berry	1
+ PDF	Bayesian clinical trials: no more excuses	2009	Mithat Gönen	1
+ PDF	Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials	2015	P. Thall Patricia S. Fox J. Kyle Wathen	1
+ PDF	A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation	2014	Chunyan Cai Suyu Liu Ying Yuan	1
+	The chart trials: Bayesian design and monitoring in practice	1994	Mahesh Parmar David J. Spiegelhalter Laurence S. Freedman	1
+ PDF	Translation of Innovative Designs Into Phase I Trials	2007	André Rogatko David J. Schoeneck William Jonas Mourad Tighiouart Fadlo R. Khuri Alan L. Porter	1
+	A group sequential, response-adaptive design for randomized clinical trials	2003	Theodore Karrison Dezheng Huo Rick Chappell	1
+ PDF	Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine	2008	Xian Zhou Suyu Liu Edward S. Kim Roy S. Herbst J. Jack Lee	1
+	Bayesian adaptive clinical trials: a dream for statisticians only?	2011	Sylvie Chevret	1
+ PDF	Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study	2015	Timothy C. Guetterman Michael D. Fetters Laurie J. Legocki Samkeliso Mawocha William G. Barsan Roger Lewis Donald A. Berry William J. Meurer	1
+ PDF	Controlled multi-arm platform design using predictive probability	2016	Brian P. Hobbs Nan Chen J. Jack Lee	1
+	Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease	2016	Andrew Satlin Sheng Wang Veronika Logovinsky Scott Berry Chad J. Swanson Shobha Dhadda Donald A. Berry	1
+ PDF	Two-Stage Marker-Stratified Clinical Trial Design in the Presence of Biomarker Misclassification	2016	Yong Zang J. Jack Lee Ying Yuan	1
+	Selection of the effect size for sample size determination for a continuous response in a superiority clinical trial using a hybrid classical and Bayesian procedure	2016	Maria Ciarleglio Christopher D. Arendt Peter Peduzzi	1
+	Efficiencies of platform clinical trials: A vision of the future	2016	Benjamin R. Saville Scott Berry	1